AI drug discovery company

Orbis Medicines

Data as of Oct 17, 2026.

Company facts

Founded

2021

ReportedSource for founded (opens in new tab)
Headquarters

Denmark (Copenhagen)

ReportedSource for headquarters (opens in new tab)
Total funding

EUR 116M (approx. $120.9M)

ConfirmedSource for total funding (opens in new tab)

Latest funding round

Round: Series A
Date: Jan 2025
Amount: EUR 90M (approx. $93.8M)
Lead investor: NEA

ConfirmedSource for the latest round (opens in new tab)

Drug discovery partners

1 pharma. Pharma here means a company with approved products and roughly $1B or more in annual revenue.

Novo Nordisk Pharma

Discovery collaboration and license and equity, Sep 17, 2026

$1.4B total potential (upfront not disclosed)

ConfirmedSource for Novo Nordisk (opens in new tab)

Recent news

Sep 18, 2026

Bloomberg: Novo partnership on next-generation cardiometabolic pills

ReportedSource (opens in new tab)
Sep 17, 2026

Discovery collaboration and license and equity with Novo Nordisk ($1.4B total potential (upfront not disclosed))

ConfirmedSource (opens in new tab)
Jan 2025

Series A: EUR 90M (approx. $93.8M)

ConfirmedSource (opens in new tab)

Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.

Spot an error? Tell me and I'll fix it.